Evidence-Based Clinical Practice Guideline for Renal Cell Carcinoma: The Japanese Urological Association 2011 update
Author:
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1442-2042.2012.03031.x/fullpdf
Reference32 articles.
1. Evidence-based clinical practice guidelines for renal cell carcinoma (Summary - JUA 2007 Edition);Fujioka;Int. J. Urol.,2009
2. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma;Ito;Int. J. Urol.,2006
3. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy;Tatokoro;J. Urol.,2008
4. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score;Iimura;J. Urol.,2009
5. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients;Naito;Eur. Urol.,2010
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Japanese registry study and systematic review of particle therapy for renal cell carcinoma;Journal of Radiation Research;2023-04-12
2. Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and De Ritis ratio with mortality in renal cell carcinoma: A multicenter analysis;Frontiers in Oncology;2022-11-24
3. Phase I/ II study of multipeptide cancer vaccine IMA901 after single‐dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long‐term follow up;International Journal of Urology;2022-10-28
4. Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy;Medicine;2022-08-12
5. Preoperative Elevation of C-Reactive Protein Is a Predictor for Adverse Oncologic Survival Outcomes for Renal Cell Carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC);Clinical Genitourinary Cancer;2021-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3